Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Meiji Seika Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Meiji Seika Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Meiji Seika Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Meiji Seika Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Meiji Seika Pharma Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Meiji Seika Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Meiji Seika Pharma Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Meiji Seika Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Meiji Seika Pharma Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Meiji Seika Pharma Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Meiji Seika Pharma Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Meiji Seika Pharma Co., Ltd. Snapshot 5
Meiji Seika Pharma Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Meiji Seika Pharma Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Meiji Seika Pharma Co., Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Meiji Seika Pharma Co., Ltd. - Pipeline Products Glance 12
Meiji Seika Pharma Co., Ltd. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Meiji Seika Pharma Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Meiji Seika Pharma Co., Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Meiji Seika Pharma Co., Ltd. - Drug Profiles 17
talaporfin sodium 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
asenapine maleate 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
fluvoxamine maleate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ME-1111 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
mirtazapine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
udenafil 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ziprasidone hydrochloride 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
arbekacin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
OP-0595 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
safinamide 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
trastuzumab biosimilar 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CP-9531 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Meiji Seika Pharma Co., Ltd. - Pipeline Analysis 34
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target 34
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Route of Administration 35
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Molecule Type 36
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action 37
Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates 38
Meiji Seika Pharma Co., Ltd. - Dormant Projects 42
Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
AM-831 43
ME-3738 43
Meiji Seika Pharma Co., Ltd. - Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Meiji Seika Pharma Co., Ltd., Key Information 5
Meiji Seika Pharma Co., Ltd., Key Facts 5
Meiji Seika Pharma Co., Ltd. - Pipeline by Indication, 2014 7
Meiji Seika Pharma Co., Ltd. - Pipeline by Stage of Development, 2014 8
Meiji Seika Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2014 9
Meiji Seika Pharma Co., Ltd. - Partnered Products in Pipeline, 2014 10
Meiji Seika Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 11
Meiji Seika Pharma Co., Ltd. - Pre-Registration, 2014 12
Meiji Seika Pharma Co., Ltd. - Phase III, 2014 13
Meiji Seika Pharma Co., Ltd. - Phase II, 2014 14
Meiji Seika Pharma Co., Ltd. - Phase I, 2014 15
Meiji Seika Pharma Co., Ltd. - Preclinical, 2014 16
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target, 2014 34
Meiji Seika Pharma Co., Ltd. - Pipeline by Route of Administration, 2014 35
Meiji Seika Pharma Co., Ltd. - Pipeline by Molecule Type, 2014 36
Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 37
Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates, 2014 38
Meiji Seika Pharma Co., Ltd. - Dormant Developmental Projects,2014 42
Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products, 2014 43